Vanguard Group Inc ownership in 2B30 / Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc.

DE ˙ DB ˙ US98422E1038

4,98 € ↓ -0,09 (-1,79%)

2026-06-04
AKTIENPREIS

Security	DE:2B30 / Xeris Biopharma Holdings, Inc.
Institution	Vanguard Group Inc
Latest Disclosed Ownership	0 shares
Ownership	0.00%

2026-03-27 - Vanguard Group Inc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 0 shares of Xeris Biopharma Holdings, Inc. (DE:2B30). This represents 0.0 percent ownership of the company. In their previous filing dated 2026-01-30 , Vanguard Group Inc had reported owning 11,186,677 shares, indicating a decrease of -100.00 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2026-03-27	2026-03-27	13G/A	11,186,677	0	-100.00	0.00	-100.00
2026-01-30	2026-01-30	13G/A	7,086,345	11,186,677	57.86	6.74	31.38
2024-02-13	2024-02-13	13G		7,086,345		5.13

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-01-29	2025-12-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	11,186,677	1,358,760	13.83	87,815	9.77	0.0013
2025-11-07	2025-09-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	9,827,917	10,980	0.11	79,999	74.50	0.0012
2025-08-11	2025-06-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	9,816,937	1,707,293	21.05	45,845	2.97	0.0007
2025-05-09	2025-03-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	8,109,644	210,581	2.67	44,522	66.27	0.0008
2025-02-11	2024-12-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	7,899,063	133,738	1.72	26,778	20.99	0.0005
2024-11-13	2024-09-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	7,765,325	108,435	1.42	22,131	28.46	0.0004
2024-08-13	2024-06-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	7,656,890	50,648	0.67	17,228	2.49	0.0003
2024-05-10	2024-03-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	7,606,242	519,897	7.34	16,810	0.94	0.0003
2024-03-11	2023-12-31	13F/A-1	XERIS BIOPHARMA HOLDINGS	COM	98422E103	7,086,345	60,181	0.86	16,653	27.43	0.0004
2024-02-14	2023-12-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	7,086,345	60,181		16,653		0.0003
2023-12-18	2023-09-30	13F/A-1	XERIS BIOPHARMA HOLDINGS	COM	98422E103	7,026,164	74,565	1.07	13,069	-28.25	0.0003
2023-11-14	2023-09-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	7,026,164	74,565		13,069		0.0001
2023-08-14	2023-06-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	6,951,599	110,515	1.62	18,213	63.35	0.0004
2023-07-14	2023-03-31	13F/A-1	XERIS BIOPHARMA HOLDINGS	COM	98422E103	6,841,084	243,128	3.68	11,151	27.07	0.0003
2023-05-15	2023-03-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	6,841,084	243,128		11,151		0.0001
2023-02-10	2022-12-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	6,597,956	88,223	1.36	8,775	-13.60	0.0002
2022-11-14	2022-09-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	6,509,733	216,252	3.44	10,156	4.79	0.0003
2022-08-12	2022-06-30	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	6,293,481	1,085,295	20.84	9,692	-27.31	0.0003
2022-05-13	2022-03-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	5,208,186	92,563	1.81	13,333	-11.05	0.0003
2022-02-14	2021-12-31	13F	XERIS BIOPHARMA HOLDINGS	COM	98422E103	5,115,623	5,115,623		14,989		0.0003

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.